SCIENTIFIC ADVISORY BOARD

Folke Sjoberg, Professor, MD, PhD

Folke Sjoberg Professor Sjoberg is a world-renowned, leading expert in the field of burn care/wound healing/tissue repair. He is Professor of Burn Surgery/Critical Care, Department of Clinical and Experimental Medicine (IKE), Linköping University and the Burn Center, Depts. of Hand, Plastic Surgery and Intensive Care, Linköping University Hospital, Linköping, Sweden. Since 2005 he is member Executive Committee of International Society For Burn Injuries and Program Chair since 2011. From 2007 to 2009 he served as President of the European Burns Association and since 2011 he is a board member of the Verification Committee, American Burn Association. He is coauthor of more than 200 peer reviewed publications, eight books. He has supervised 40 PhD students, about 20 dissertations, and served as primary investigator of 150 clinical trials Phase 1-4. He received his MD in 1983, and PhD in 1990, both from Linkoping University. He is a prolific lecturer at conferences around the world, and serves on the editorial board of seven International Journals.

 


Christopher H Evans, Professor, PhD

Christopher Evans Professor Evans is a leading expert in the field of tissue repair and new treatment modalities, including gene therapy in arthritis. He is currently Director of the Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, and Professor of Orthopedics, Physical Medicine and Rehabilitation. He previously served as Director of Center for Advanced Orthopedic Studies, Beth Israel Deaconess  Medical Center, Harvard Medical School. and is Maurice Müller Professor of Orthopaedic Surgery Emeritus, Harvard Medical School. Originally from Great Britain, Dr. Evans holds a bachelor's degree in genetics and microbiology, a Ph.D. in biochemistry from the University of Wales, a master's degree in history and philosophy of science from the University of Pittsburgh, and a D.Sc. from the University of Wales. He is the author of more than 300 peer reviewed scientific publications. He served as President Orthopedic Research Society 2004 -2005, and has served as the Chair, Scientific Advisory Board, Journal of Orthopedic Research . In 2009 he won the Marshall R Urist MD Award, Orthopedic Research Society for excellence in tissue regeneration, and in 2010 the Arthur Steidler MD Award, Orthopedic Research Society for understanding of the musculoskeletal system. In 2016 he was elected an inaugural Fellow of International Orthopaedic Research (FIOR).

 


 

Dr. Larry A. Couture

Larry CoutureDr. Couture’s recognized expertise–established over nearly three decades of work with experimental biologics, heavily focused on cell and gene therapies–includes organizational management, regulatory affairs, business development, process development, GMP manufacturing and clinical development. Dr. Couture was a key participant in numerous first-in-man clinical studies, including the first human gene therapy trials, the first direct administration to humans of a genetically engineered virus, and many other cell and gene therapy firsts. He currently serves as CEO of Orbsen Therapeutics, LTD, and Arrogene,Inc. Dr. Couture was the Founding Director and Senior Vice President of the Center for Applied Technology (CAT) at City of Hope where he established and oversaw the offices of IND Development and Regulatory Affairs, Quality Systems, Technology Licensing and COH’s two precedent setting GMP biologics manufacturing facilities, the Center for Biomedicine and Genetics and the Cell Therapy Production Center. Dr. Couture directed the successful production of over 300 lots of clinical grade viral vectors, vaccines, plasmid DNA, monoclonal antibodies, bacterial products and hematopoietic cell-based therapeutics and pluripotent stem cell derived cell products including: cardiomyocytes, retinal pigment epithelia, neural stem and progenitor cells and dopaminergic neurons. Lentivirus vectors produced at the CAT have been used by over a half dozen groups in clinical trials across the country, including those resulting in the first reported successful clinical outcomes in leukemia with CAR-T immunotherapeutics. At COH, Dr. Couture oversaw a combined staff of approximately 60 scientists and technical staff. He oversaw nearly 50 active INDs and was a member of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, as well as several FDA working groups. In addition to currently leading two biotechnology companies and consulting with or participating on the advisory boards of a number of additional biotechnology companies, he has been an ad hoc analyst for venture capital firms and has mentored many start-up companies in the Southern California area. He previously founded and/or served as Director or CEO of several biotechnology companies including Cell City, Genbasix, Aliva Biopharmaceuticals, and eMTA Commons, Inc., and held senior scientist and management positions at Genzyme Corporation and Ribozyme Pharmaceuticals.

 


Dr. C. Glenn Begley, MD, PhD

Glenn BegleyDr. Glenn Begley has over 30 years’ experience of translational medicine including 10 years as Vice-President and Global Head of Hematology and Oncology at Amgen, where he was responsible for building the hematology and oncology research program and advancing 24 molecules into clinical development. Before joining Amgen in 2002, Dr. Begley also gained over 20 years of clinical experience in medical oncology and hematology. His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells and hastened hematopoietic recovery compared with bone marrow transplantation. This finding has revolutionized the approach to hematopoietic cell transplantation. He has held several academic positions including Executive Director at the Western Australian Institute of Medical Research, and Senior Principal Research Fellow and Professor of Medicine at the University of Melbourne at Walter and Eliza Hall Institute of Medical Research. He is also holds a PhD in cellular and molecular biology and has authored, more than 220 scientific publications including the biological characterization of recombinant G-CSF and GM-CSF in 1986.